Hematology-Oncology – Page 3

Tailoring Transplant Conditioning and Maintenance Therapy in FLT3-ITD AML: Insights on NPM1 Mutations and Measurable Residual Disease

By MedXY 11/04/2025

Posttransplant gilteritinib greatly benefits FLT3-ITD AML patients with NPM1 comutations, while myeloablative conditioning offers limited advantages over reduced-intensity conditioning in eradicating measurable residual disease.

$Belantamab Mafodotin Plus Bortezomib and Dexamethasone Significantly Improves Overall Survival in Relapsed/Refractory Multiple Myeloma: Updated DREAMM-7 Results$

Hematology-Oncology news

Belantamab Mafodotin Plus Bortezomib and Dexamethasone Significantly Improves Overall Survival in Relapsed/Refractory Multiple Myeloma: Updated DREAMM-7 Results

By MedXY 11/04/2025

The DREAMM-7 phase 3 trial shows that belantamab mafodotin combined with bortezomib and dexamethasone produces early, sustained, and statistically significant overall survival and deep, durable responses versus daratumumab-based therapy in relapsed/refractory multiple myeloma.

Hematology-Oncology news Pediatrics

Understanding ‘Favism’: Diagnosis, Treatment, and Living with G6PD Deficiency

By MedXY 11/01/2025

Favism, a hereditary enzyme deficiency causing red blood cell breakdown upon exposure to certain triggers like fava beans, is preventable with proper diagnosis and management. This article explores its clinical features, diagnosis, treatment, and lifestyle adaptations.

Hematology-Oncology news

Selective JAK2 Inhibition OB756 Shows Promise in Hydroxyurea/Interferon‑Intolerant or -Resistant Essential Thrombocythemia

By MedXY 11/01/2025

A Phase II multicenter study reports that OB756, a selective JAK2 inhibitor, is active and reasonably well tolerated in hydroxyurea- or interferon-intolerant/resistant essential thrombocythemia, producing platelet and leukocyte control, spleen volume reduction, symptom improvement and reductions in JAK2 V617F allele burden.

Hematology-Oncology news

CM313, a Novel Anti-CD38 Monoclonal Antibody, Demonstrates Promising Efficacy and Safety in Persistent or Chronic Primary Immune Thrombocytopenia: Insights from a Phase 2 Randomized Trial

By MedXY 10/31/2025

The phase 2 trial shows that CM313 significantly improves platelet response rates and duration with manageable safety in adults with persistent or chronic primary immune thrombocytopenia.

Emergency Medicine Hematology-Oncology news Pediatrics

Timely Opioid Administration in Pediatric Emergency Departments Reduces Hospitalizations for Acute Sickle Cell Pain

By MedXY 10/27/2025

Prompt opioid delivery in pediatric EDs for sickle cell pain significantly lowers hospitalization rates, with the greatest benefit seen when the first dose is given within 60 minutes and the second dose within 30 minutes.

Allergy & Immunology Hematology-Oncology news

Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency

By MedXY 10/25/2025

This study demonstrates the long-term effectiveness and safety of autologous gene therapy for treating ADA deficiency, showing sustained immune function and minimal adverse effects over a median follow-up of 7.5 years.

Hematology-Oncology

From Discovery to Breakthroughs: How Multiple Myeloma Survival Has Doubled in 20 Years

By MedXY 10/24/2025

Over the past two decades, advances in therapy have doubled the median survival of multiple myeloma patients, transforming this once devastating cancer into a more manageable disease through targeted drugs and immune therapies.

Hematology-Oncology news Ophthalmology

Advances in Targeted and Gene Therapies: Promising Data on KRAS G12D Inhibitors, DR5 Agonists, and Ocular Gene Therapy

By MedXY 10/24/2025

Recent clinical trials report encouraging tumor shrinkage with KRAS G12D inhibitor VS-7375, significant progression-free survival benefit in soft tissue sarcoma with ozekibart, and a novel gene therapy acquisition targeting wet AMD.

Dermatology Hematology-Oncology news

T-Cell Receptor Clonotypes as Prognostic Markers in Cutaneous T-Cell Lymphoma: Insights from Next-Generation Sequencing

By MedXY 10/24/2025

This study identifies specific T-cell receptor clonotypes associated with aggressive subtypes and poorer survival in mycosis fungoides and Sézary syndrome, supporting TCR sequencing as a tool for refined risk stratification in cutaneous T-cell lymphoma.

Hematology-Oncology news Pediatrics

Eltrombopag in Newly Diagnosed Pediatric Immune Thrombocytopenia: A Breakthrough in Early Treatment Strategy

By MedXY 10/24/2025

This randomized trial demonstrates that eltrombopag significantly improves sustained platelet response in children with newly diagnosed ITP, offering a potential early intervention option.

Hematology-Oncology OB/GYN & Women's Health Specialties

Ki-67 Dynamics During Neoadjuvant Chemotherapy: A Key to Better Breast Cancer Prognosis

By MedXY 10/18/2025

This study highlights the prognostic significance of tumor Ki-67 changes during neoadjuvant treatment, offering potential for improved risk stratification and personalized therapy in breast cancer patients.

Hematology-Oncology Specialties

Restrictive Treatment Criteria Improve Prognosis Prediction in Chronic Lymphocytic Leukemia: Insights from the Brazilian Registry

By MedXY 10/18/2025

A restrictive treatment initiation approach in CLL, endorsed by the Brazilian Group of CLL, identifies patients with higher risk more accurately and spares low-risk patients from unnecessary therapy, showing superior prognostic stratification compared to international guidelines.

Hematology-Oncology news Oncology Specialties

Optimizing Treatment in Frail Elderly with Newly Diagnosed Multiple Myeloma: Insights from the IFM2017-03 Trial on Dexamethasone-Sparing Daratumumab and Lenalidomide Regimen

By MedXY 10/15/2025

The IFM2017-03 phase 3 trial demonstrates that a dexamethasone-sparing regimen combining daratumumab with lenalidomide markedly improves progression-free survival in frail elderly multiple myeloma patients, without increasing serious adverse events.

Cardiology Hematology-Oncology news

Clonal Hematopoiesis in Older Adults: Implications for Cardiovascular Risk, Bleeding, and Aspirin Use

By MedXY 10/15/2025

This study reveals that clonal hematopoiesis of indeterminate potential (CHIP) in adults aged 70+ does not increase cardiovascular risk but is associated with heightened bleeding risk. Aspirin showed no additional benefits or harms for those with CHIP in primary prevention of cardiovascular events.

Hematology-Oncology news

Innovative Combination Therapy with Talquetamab and Daratumumab Shows Promise in Heavily Pretreated Multiple Myeloma

By MedXY 10/14/2025

The TRIMM-2 study reveals that talquetamab plus daratumumab yields high response rates and durable disease control in relapsed/refractory multiple myeloma with manageable safety, offering a novel combination strategy for heavily pretreated patients.

Hematology-Oncology news Rheumatology

Azacitidine Shows Promising Efficacy and Safety in Treating VEXAS Syndrome: Insights from a Large-Scale Retrospective FRENVEX Study

By MedXY 10/14/2025

A retrospective study of 88 patients with genetically confirmed VEXAS syndrome reveals that azacitidine improves inflammatory symptoms, cytopenias, and reduces UBA1 mutant clone burden with an acceptable safety profile, supporting its use and need for prospective trials.

Hematology-Oncology news Oncology

Defining a Distinct Subtype of TP53-Mutated AML via BAP1 Loss: Implications for Targeted Therapy with BCL-xL Inhibitors

By MedXY 10/14/2025

Loss of the tumor suppressor BAP1 characterizes a unique subtype of TP53-mutated de novo acute myeloid leukemia (AML), correlating with poorer prognosis and erythroid lineage priming, while revealing vulnerability to BCL-xL inhibition as a promising therapeutic strategy.

Hematology-Oncology news Rheumatology

UBA6: A Novel Therapeutic Vulnerability in VEXAS Syndrome Unveiled by E1 Enzyme Dependency Profiling

By MedXY 10/14/2025

This study characterizes UBA1 mutation effects in VEXAS syndrome and identifies UBA6 as a compensatory enzyme and promising therapeutic target, highlighting selective inhibition to combat mutant hematopoietic clones.

Hematology-Oncology Rheumatology Specialties

VEXAS Anemia: Unraveling the Mosaic Erythroblastopenia in a Novel Autoinflammatory Syndrome

By MedXY 10/14/2025

This study reveals that VEXAS syndrome-associated anemia results from a mosaic erythroblastopenia due to selective UBA1 mutations in early erythroid precursors, advancing understanding of its pathophysiology and therapeutic implications.